Tag
A pooled analysis of 11,269 patients from the INTERACT and ATACH-II trials reveals that 24-hour systolic blood pressure trajectories, rather than just single targets, significantly influence functional outcomes after intracerebral hemorrhag
This systematic review analyzes the profound underrepresentation of African populations in high-impact clinical trials, revealing a stark disparity in cardiovascular and general medical research that limits the global applicability of evide
The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.
The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and
This review evaluates the LIDA trial’s findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.
A Phase 3 pragmatic trial found that 12 hours of weekly intensive task-specific training added to usual care does not improve motor recovery in recent spinal cord injury patients, suggesting a potential plateau in the benefits of early reha
This review evaluates a recent 2-year pilot RCT on low-dose lithium carbonate for MCI, synthesizing its findings with emerging evidence on Aβ clearance, gut-brain axis modulation, and multimodal disease forecasting.
A pivotal triple-crossover RCT reveals that while bisoprolol reduces exercise capacity and worsens diastolic markers in nonobstructive HCM, verapamil maintains exercise performance and improves myocardial strain.
The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alte
This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients
The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.
A nationwide Swedish registry analysis demonstrates that routine PCI before TAVR for significant coronary artery disease does not improve survival or reduce urgent revascularization, but significantly increases bleeding risk while reducing
This review synthesizes practice-changing pediatric research, highlighting how device selection in acute wheezing, automated oxygen titration in neonates, and novel siRNA therapies for hypercholesterolemia are redefining clinical standards
The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for o
The PERMET randomized clinical trial found that metformin did not improve the 6-minute walk distance or secondary walking outcomes in patients with peripheral artery disease without diabetes, suggesting no benefit for functional impairment
A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an inter
The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping cl
The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist
The STRIDES trial, the largest of its kind, demonstrates that isotonic drinks, extended rest, modified muscle tension, and psychosocial support do not significantly reduce vasovagal reactions in blood donors compared to existing UK standard
A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i
